Physician profile
Sofy Landes
NPI 1265790133
$5,278.08
in general payments reported to CMS, 2019-2025
34 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $434 · 2021: $908 · 2022: $1,082 · 2023: $1,432 · 2024: $491 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $839.39 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $518.35 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.58 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $402.26 | 2019-2023 | Farxiga |
| Heartflow, INC. | $285.19 | 2025 | |
| Merck Sharp & Dohme LLC | $279.40 | 2021-2023 | Verquvo |
| Amgen INC. | $263.88 | 2019-2024 | Repatha |
| Inari Medical, INC. | $252.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $246.65 | 2019-2024 | |
| Pfizer INC. | $236.69 | 2019-2024 | |
| Medtronic, INC. | $234.39 | 2021-2024 | Azure Xt Dr Mri Surescan, Tyrx, Linq II |
| Boston Scientific Corporation | $170.38 | 2020-2023 | Watchman Flx |
| Abbott Laboratories | $118.72 | 2021-2024 | Jot Dx |
| Philips North America LLC | $107.79 | 2023-2025 | Ecc Solutions |
| Sanofi-Aventis U.S. LLC | $101.10 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $88.57 | 2023 | Zio Xt Patch |
| Medtronic Vascular, INC. | $84.16 | 2020 | |
| Alnylam Pharmaceuticals INC. | $83.65 | 2022-2023 | Onpattro |
| Scpharmaceuticals INC. | $80.53 | 2024 | |
| Arbor Pharmaceuticals, INC. | $54.33 | 2019 | |
| United Therapeutics Corporation | $54.17 | 2023-2024 | Tyvaso |
| Kiniksa Pharmaceuticals, LTD. | $45.45 | 2022-2023 | Arcalyst |
| Esperion Therapeutics, INC. | $44.36 | 2021-2024 | Nexletol |
| Teleflex LLC | $43.52 | 2023 | Langston |
| Biotronik INC. | $38.88 | 2019-2024 | Biomonitor, Amvia Edge |
| Kiniksa Pharmaceuticals International, Plc | $37.27 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $32.09 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $31.98 | 2023 | Evkeeza, Praluent |
| Actelion Pharmaceuticals US, INC. | $18.36 | 2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $16.64 | 2024 | Ozempic |
| G Medical Diagnostic Services, INC. | $14.89 | 2022 | |
| Cvrx, INC. | $13.02 | 2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofy Landes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.